Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Olalekan O. Oluwole(Vanderbilt University), Tom van Meerten(University Medical Center Groningen), Jaeyeon Kim(Sidney Kimmel Cancer Center), Zahid Bashir(AstraZeneca (United Kingdom)), Jeff McLeroy(Gilead Sciences (Australia)), Catherine Thiéblemont(Université Paris Cité), Marie José Kersten(Hovon), Caron A. Jacobson(Dana-Farber Cancer Institute), Monique C. Minnema(University Medical Center Utrecht), Abhinav Deol(Wayne State University), Lisa D. Johnson(Gilead Sciences (Australia)), John M. Timmerman(Sheba Medical Center), Lovely Goyal(Gilead Sciences (Australia)), Krimo Bouabdallah(Centre Hospitalier Universitaire de Bordeaux), Nancy L. Bartlett(Washington University in St. Louis), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Irit Avivi(Tel Aviv Sourasky Medical Center), Julie M. Vose(University of Nebraska Medical Center), André Goy(Hackensack University Medical Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Yi Lin, Umar Farooq(Wake Forest University), Peter A. McSweeney(Mesoblast (United States)), John M. Rossi(Amgen (United States)), Sophie de Guibert(Centre Hospitalier Universitaire de Rennes), Yan Zheng(First Affiliated Hospital of Xi'an Jiaotong University), Patrick J. Stiff(Loyola University Medical Center)
British Journal of Haematology
July 22, 2021
Cited by 217


Related Papers